Published in

American Association for Cancer Research, Clinical Cancer Research, 3(28), p. 438-440, 2022

DOI: 10.1158/1078-0432.ccr-21-3564

Links

Tools

Export citation

Search in Google Scholar

Using Circulating Tumor DNA for Colon Cancer Adjuvant Therapy: To Be or Not to Be?

Journal article published in 2022 by Van K. Morris ORCID, Thomas J. George ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Abstract Detection of circulating tumor DNA (ctDNA) postoperatively is prognostic for recurrence for patients with stage III colon cancer. Those with sustained undetectable ctDNA will likely be cured. Eradication of minimal residual disease (per ctDNA clearance) with chemotherapy did not occur in most ctDNA-positive patients and led to eventual disease relapse. See related article by Henriksen et al., p. 507